SGN-35C

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameSGN-35C
Drug Alias NameSGN-35CPF-08046044
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linker
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-Tumor necrosis factor receptor superfamily member 8
TargetsDNA topoisomerase ITumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyDenmark +[6] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeagen Inc
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, Diffuse +[4] 

Other Information

ATC CodeN/A
Related LinksN/A